2-Bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
| Title | Journal |
|---|---|
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | The Biochemical journal 20130415 |
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | Nature biotechnology 20111101 |
| Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20110101 |
| Differential regulation of proliferation and differentiation in neural precursor cells by the Jak pathway. | Stem cells (Dayton, Ohio) 20101001 |
| A novel indole-3-propanamide exerts its immunosuppressive activity by inhibiting JAK3 in T cells. | The Journal of pharmacology and experimental therapeutics 20091101 |
| The specificity of JAK3 kinase inhibitors. | Blood 20080215 |
| Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. | Oncogene 20070816 |
| Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. | Leukemia 20061001 |
| Interplay between epidermal growth factor receptor and Janus kinase 3 regulates polychlorinated biphenyl-induced matrix metalloproteinase-3 expression and transendothelial migration of tumor cells. | Molecular cancer research : MCR 20060601 |
| The JAK3 inhibitor WHI-P154 prevents PDGF-evoked process outgrowth in human neural precursor cells. | Journal of neurochemistry 20060401 |
| JAK inhibitors AG-490 and WHI-P154 decrease IFN-gamma-induced iNOS expression and NO production in macrophages. | Mediators of inflammation 20060101 |
| Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. | Laboratory investigation; a journal of technical methods and pathology 20051201 |
| Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner. | British journal of pharmacology 20050701 |
| IL-4-dependent CD86 expression requires JAK/STAT6 activation and is negatively regulated by PKCdelta. | Cellular signalling 20040201 |
| Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. | Science (New York, N.Y.) 20031031 |
| Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. | Transplantation 20030615 |
| Augmentation of mast cell bactericidal activity by the anti-leukemic drug, 4-(3'bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline. | Leukemia & lymphoma 20020601 |
| Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. | Endocrinology 20020201 |
| 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. | Acta crystallographica. Section C, Crystal structure communications 20010101 |
| Tyrosine kinase inhibitors against EGF receptor-positive malignancies. | Methods in molecular biology (Clifton, N.J.) 20010101 |